Cargando…

Demonstration of safety of intravenous immunoglobulin in geriatric patients in a long-term, placebo-controlled study of Alzheimer's disease

INTRODUCTION: We present safety results from a study of Gammagard Liquid intravenous immunoglobulin (IGIV) in patients with probable Alzheimer's disease. METHODS: This was a placebo-controlled double-blind study. Subjects were randomized to 400 mg/kg (n = 127), 200 mg/kg (n = 135) IGIV, or to 0...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gelmont, David, Thomas, Ronald G., Britt, Jonathan, Dyck-Jones, Jacqueline A., Doralt, Jennifer, Fritsch, Sandor, Brewer, James B., Rissman, Robert A., Aisen, Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2016
Materias:	Featured Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5644268/ https://www.ncbi.nlm.nih.gov/pubmed/29067300 http://dx.doi.org/10.1016/j.trci.2016.06.003

Ejemplares similares

A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease
por: Turner, R. Scott, et al.
Publicado: (2015)

Dissociation of Down syndrome and Alzheimer's disease effects with imaging
por: Matthews, Dawn C., et al.
Publicado: (2016)

Effects of traumatic brain injury and posttraumatic stress disorder on development of Alzheimer's disease in Vietnam Veterans using the Alzheimer's Disease Neuroimaging Initiative: Preliminary report
por: Weiner, Michael W., et al.
Publicado: (2017)

Reduction of Infusion Time Using a 10% Intravenous Immunoglobulin Formulation With a 15-Minute Rate Escalation Protocol During Staffing Shortages Due to COVID-19
por: Prosser, Barbara, et al.
Publicado: (2022)

Cross-validation of optimized composites for preclinical Alzheimer's disease
por: Donohue, Michael C., et al.
Publicado: (2016)

Contribution of Alzheimer's biomarkers and risk factors to cognitive impairment and decline across the Alzheimer's disease continuum
por: Tosun, Duygu, et al.
Publicado: (2021)

The relative efficiency of time-to-progression and continuous measures of cognition in presymptomatic Alzheimer's disease
por: Li, Dan, et al.
Publicado: (2019)

COVID-19 Pandemic, Personality and Geriatric Population: Proposed Pragmatism
por: Dubey, Souvik, et al.
Publicado: (2021)

Intravenous Cetirizine vs Intravenous Diphenhydramine for the Prevention of Hypersensitivity Infusion Reactions: Results of an Exploratory Phase 2 Study
por: Holmes, Jarrod P., et al.
Publicado: (2021)

Review of Intravenous Lipid Emulsion Therapy
por: Spray, Jeffery W.
Publicado: (2016)

The Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer's disease, including a placebo-treated noncarrier cohort
por: Tariot, Pierre N., et al.
Publicado: (2018)

Analyses of natural courses of Japanese patients with Alzheimer's disease using placebo data from placebo-controlled, randomized clinical trials: Japanese Study on the Estimation of Clinical course of Alzheimer's disease
por: Watanabe, Mitsunori, et al.
Publicado: (2019)

A simulation study comparing slope model with mixed-model repeated measure to assess cognitive data in clinical trials of Alzheimer's disease
por: Chen, Yun-Fei, et al.
Publicado: (2018)

Continuous Intravenous Milrinone Therapy in Pediatric Outpatients
por: Curley, Michelle, et al.
Publicado: (2017)

A New Force-Activated Separation Device for the Prevention of Peripheral Intravenous Restarts
por: Panza, Gregory A., et al.
Publicado: (2022)

Intravenous immunoglobulin and Alzheimer’s disease: what now?
por: Loeffler, David A
Publicado: (2013)

Intranasal Insulin Reduces White Matter Hyperintensity Progression in Association with Improvements in Cognition and CSF Biomarker Profiles in Mild Cognitive Impairment and Alzheimer’s Disease
por: Kellar, D., et al.
Publicado: (2021)

Delayed-start analysis: Mild Alzheimer's disease patients in solanezumab trials, 3.5 years
por: Liu-Seifert, Hong, et al.
Publicado: (2015)

Evaluation of the Predictive Validity of Thermography in Identifying Extravasation With Intravenous Chemotherapy Infusions
por: Matsui, Yuko, et al.
Publicado: (2017)

Primary Intravenous Set Consumption Across 3 Branded Infusion Pumps
por: Hedlund, Nancy, et al.
Publicado: (2017)

Prospective Study Evaluating Whether Standard Peripheral Intravenous Catheters Can Be Used for Blood Collection Throughout Hospital Stay
por: Psaila, Justin, et al.
Publicado: (2023)

Response to the Letter to the Editor Regarding “Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials”
por: Suez, Daniel, et al.
Publicado: (2017)

Safety Profile of HTX-019 Administered as an Intravenous Infusion in Patients With Cancer: A Retrospective Analysis
por: Calcanes, George, et al.
Publicado: (2019)

Intranasal insulin modulates cerebrospinal fluid markers of neuroinflammation in mild cognitive impairment and Alzheimer’s disease: a randomized trial
por: Kellar, Derek, et al.
Publicado: (2022)

An Application of Cmaps in the Description of Clinical Information Structure and Logic in Electronic Health Records
por: Brewer, Allen, et al.
Publicado: (2012)

Development of Written Materials for Participants in an Alzheimer's Disease and Related Dementias Screening Trial
por: Head, Katharine J, et al.
Publicado: (2022)

Intravenous Smart Pumps During Actual Clinical Use: A Descriptive Comparison of Primary and Secondary Infusion Practices
por: Giuliano, Karen K., et al.
Publicado: (2021)

First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer's disease
por: Ferrero, James, et al.
Publicado: (2016)

Intermittent hypoxic–hyperoxic training on cognitive performance in geriatric patients
por: Bayer, Urike, et al.
Publicado: (2017)

A blood screening tool for detecting mild cognitive impairment and Alzheimer's disease among community‐dwelling Mexican Americans and non‐Hispanic Whites: A method for increasing representation of diverse populations in clinical research
por: O'Bryant, Sid E., et al.
Publicado: (2021)

Should development of Alzheimer’s disease-specific intravenous immunoglobulin be considered?
por: Loeffler, David A
Publicado: (2014)

Placebos and Medical Education
por: Raz, Amir, et al.
Publicado: (2008)

A randomized, double-blind, placebo-controlled trial of resveratrol with glucose and malate (RGM) to slow the progression of Alzheimer's disease: A pilot study
por: Zhu, Carolyn W., et al.
Publicado: (2018)

The down syndrome biomarker initiative (DSBI) pilot: proof of concept for deep phenotyping of Alzheimer’s disease biomarkers in down syndrome
por: Rafii, Michael S., et al.
Publicado: (2015)

Innovative Use of Existing Public and Private Data Sources for Postmarketing Surveillance of Central Line-Associated Bloodstream Infections Associated With Intravenous Needleless Connectors
por: Tabak, Ying P., et al.
Publicado: (2016)

In vivo measurement of widespread synaptic loss in Alzheimer's disease with SV2A PET
por: Mecca, Adam P., et al.
Publicado: (2020)

The Role of the Placebo in Clinical Practice
por: Lichtenberg, Pesach
Publicado: (2008)

A 24-week double-blind placebo-controlled study of the efficacy and safety of the AMPA modulator S47445 in patients with mild to moderate Alzheimer's disease and depressive symptoms
por: Bernard, Katy, et al.
Publicado: (2019)

Erratum: Should development of Alzheimer’s disease-specific intravenous immunoglobulin be considered?
por: Loeffler, David A
Publicado: (2015)

The Alzheimer's disease THErapy with NEuroaid (ATHENE) study protocol: Assessing the safety and efficacy of Neuroaid II (MLC901) in patients with mild-to-moderate Alzheimer's disease stable on cholinesterase inhibitors or memantine—A randomized, double-blind, placebo-controlled trial
por: Chen, Christopher L.H., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_q1u5qaq97vu2o2uaammslp061q